

Contents

<i>Foreword</i>	vii
<i>Acknowledgements</i>	xii
<i>Table of Cases</i>	xvii
<i>Table of Legislation</i>	xxv
Introduction	1
Part I Background	
1 Innovation Incentives	9
2 International IP Cooperation and Developing Country Perspectives	29
3 Biotech Inventions and Patentable Subject Matter	59
Part II The TRIPS Agreement	
4 Uruguay Round Negotiations and the Adoption of TRIPS	105
5 The TRIPS Agreement <i>de Lege Lata</i> : the Outline	148
6 Various Methods of Interpretation: WTO Agreements and the Vienna Convention on the Law of Treaties	190
7 TRIPS Provisions as Interpreted by the WTO Dispute Settlement Organs	209
Part III Access to Medicines	
8 The AIDS Epidemic and TRIPS	261
9 Doha Declaration and Beyond	304
Part IV IP and Industrial Policies	
10 Emerging Economies' IP and Industrial Policies	345
11 Pharmaceutical Industries, R&D and Public Health in Emerging Economies	388
Part V TRIPS Flexibilities and National Implementation	
12 TRIPS Flexibilities and National Implementation (1) Patentable Subject Matter and Patentability Requirements	419
13 TRIPS Flexibilities and National Implementation (2) Protection of Test Data Submitted to Regulatory Authorities	469

xvi *Contents*

14	'TRIPS Plus' Provisions in US Free Trade Agreements	480
----	---	-----

Part VI Interpreting TRIPS for Innovation

15	Recasting the Debate on Intellectual Property Rights	513
----	--	-----

	<i>Index</i>	521
--	--------------	-----